Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy.
The mammalian innate immune system has the ability to recognise and direct a response against incoming foreign DNA. The primary signal that triggers this response is unmethylated CpG motifs present in the DNA sequence of various disease-causing pathogens. These motifs are rare in vertebrate DNA, but abundant in bacterial and some viral DNAs. Because gene therapy generally involves the delivery of DNA from either plasmids of bacterial origin or recombinant viruses, an acute inflammatory response of variable severity inevitably results. The response is most serious for non-viral gene delivery vectors composed of cationic lipid-DNA complexes, producing adverse effects at lower doses and lethality at higher doses of complex. This review examines the role of immunostimulatory CpG motifs in the acute inflammatory response to non-viral gene therapy vectors. Strategies to neutralise or eliminate CpG motifs within plasmid DNA vectors, and the existing limitations of CpG reduction on improving the safety profile of non-viral vectors, will be discussed.
Yew
Nelson S
NS
Genzyme Corporation, 31 New York Avenue, Framingham, MA 01701-9322, USA. Nelson.Yew@genzyme.com
Cheng
Seng H
SH
D000818:Animals; D018899:CpG Islands / Q000235:genetics*; D004247:DNA / Q000008:administration & dosage / Q000009:adverse effects* / Q000235:genetics; D015316:Genetic Therapy / Q000009:adverse effects* / Q000379:methods; D005822:Genetic Vectors / Q000008:administration & dosage / Q000009:adverse effects* / Q000235:genetics; D006801:Humans; D007113:Immunity, Innate; D007249:Inflammation / Q000276:immunology*; D010957:Plasmids / Q000008:administration & dosage / Q000009:adverse effects* / Q000235:genetics
D004247:DNA